Your browser doesn't support javascript.
loading
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis.
Kovanda, Laura L; Sass, Gabriele; Martinez, Marife; Clemons, Karl V; Nazik, Hasan; Kitt, Therese M; Wiederhold, Nathan; Hope, William W; Stevens, David A.
  • Kovanda LL; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA laura.kovanda@astellas.com.
  • Sass G; California Institute for Medical Research, San Jose, California, USA.
  • Martinez M; California Institute for Medical Research, San Jose, California, USA.
  • Clemons KV; California Institute for Medical Research, San Jose, California, USA.
  • Nazik H; California Institute for Medical Research, San Jose, California, USA.
  • Kitt TM; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
  • Wiederhold N; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Hope WW; Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Stevens DA; Royal Liverpool and Broadgreen University Hospital Trust, Liverpool Health Partners, Liverpool, United Kingdom.
Article en En | MEDLINE | ID: mdl-33782009
ABSTRACT
Coccidioides spp. are important pathogens in regions where they are endemic, and new treatment options are needed. Here, isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. Broth macrodilution was performed on Coccidioides isolates to measure minimal effective concentrations (MEC) and minimal fungicidal concentrations (MFC). Mice were inoculated with Coccidioides posadasii (Silveira strain). Treatment started 4 days postinoculation. In model 1, mice were treated for 19 days, followed by 30 days of off-therapy observation, measuring survival through day 49 and residual fungal burden. Treatments included ISAVUSULF (prodrug; 186, 279, or 372 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Model 2 included 7-day treatment with ISAVUSULF (prodrug; 74.4, 111.6, or 148.8 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Serial plasma and tissues samples were obtained for pharmacokinetics (PK) and fungal burden measurement, respectively. Fifty percent minimal effective concentration (MEC50) values were 0.39 mg/liter (isavuconazole [ISAV]) and 12.5 mg/liter (FLU). Treatment with ISAVUSULF186 or with either FLU dose resulted in higher survival compared to that in the untreated group. Treatment with ISAVUSULF186 or ISAVUSULF279 twice daily or FLU100 reduced fungal burden in all organs (model 1). In model 2, a >1 log10 CFU/organ reduction was demonstrated, with ISAV area under the concentration-time curve (AUC) values achieved with 111.6 mg/kg twice daily (56.8 mg · h/liter) in the spleen and liver. FLU AUC values of 100 and 500 mg·h/liter for 20 and 100 mg/kg doses, respectively, resulted in a >1 log10 CFU/organ mean reduction in all organs. ISAVUSULF and FLU improved survival and reduced fungal burden. Increasing plasma drug exposures resulted in decreases in fungal burden.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Coccidioidomicosis Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Coccidioidomicosis Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article